Hållbar UPPHANDLING
Ett samarbete mellan Sveriges regioner

Summary of audit result

Below is a summary of a follow-up review of sustainability requirements concerning a supplier to Sweden's regions. The summary presents the audit results and the activities carried out as a consequence of them. The summary has been updated progressively as new activities related to the follow-up were completed, until all potential non-conformities had been addressed and the follow-up was considered closed.

For questions regarding the summary, please contact the Regional Office for Sustainable Procurement.

www.husr.se

Log

Updated	2026-02-25

General information

Supplier	Baxter Medical AB
Regions with announced contracts	Region of Västra Götaland
Risk area	Pharmaceuticals
Product	Cytostatic drug
Type of follow-up	Digital office audit
Requirements	Sustainable supply chains and systematic environmental work
Date for audit	2026-01-22
For more information	Jenny Forsell Skoog Västra Götalandsregionen, jenny.forsell.skoog@vgregion.se

Summary of the audit	During the follow-up audit, Baxter demonstrated openness and willingness to engage in the audit process and presented improvements since the previous audit. Baxter has strengthened its work related to supplier risk management through established tools and processes and has demonstrated a functioning and documented deviation management process, including recorded cases and follow-up actions. However, Baxter does not yet fulfil the requirements related to risk analysis and systematic follow-up in the supply chain for the sampled product. Continued development is required to ensure that the risk analysis and follow-up activities are based on prioritized and severe risks throughout the supply chain.

Audit result

Sustainable supply chain	**Criteria***
1. Risk analysis	
2. Monitoring	

Description	
Deviation	
No identified deviations	

*For a more detailed description see appendix 1. Deviations.

Next step	See attached action plan in appendix 1

Appendix 1 - deviations

	Sustainable supply chains
Deviation	Risk analysis: Baxter has not demonstrated a risk analysis covering the supply chain for the goods covered by the contract, including prioritized risks in its value chain.
Suppliers action	1. Engage an outside consultant to guide Baxter with establishing a comprehensive supply chain ESG-risk assessment approach that is aligned to international frameworks (e.g., OECD, UNGP and ILO) and industry practices. (Completed) 2. Baxter will demonstrate a systematic approach for supply chain risk assessment that includes identifying and prioritizing potential risks in the entire end to end supply chain, including upstream supply chain. To achieve this, we plan to (not exhaustive): 2.1. Continue to assess current and potential risk in the supply chain tiers to identify high-risk suppliers for the sample product. Assessment will be based on certain risk criteria (e.g., presence of conflict, weak rule of law, high rates of corruption) and will also consider the geographical location of the operations and the products and services involved (e.g., child labor, labor laws, use of chemicals, heavy equipment). In assessing suppliers, Baxter will integrate relevant external indices and internationally recognized sources (including OECD, ILO, and UNGP frameworks) into its updated risk assessment methodology in a systematic manner. 2.2 For identified high-risk suppliers, continue to perform mapping of the entire end to end supply chain. In the time frame specified, Baxter will focus on completing the mapping of entire supply chain for in-scope product (Caelyx). (Status – is in progress, First and Second tiers complete) 2.3. For identified high-risk suppliers, continue to assess and prioritize the current and potential risks of adverse impacts. Baxter will use information from credible and independent sources if consultations are not possible in the supply chains of high-risk suppliers. 3. Update policies and procedures to reflect the updated systematic approach for end to end supply chain risk assessment including continuous identification and severity-based prioritization.
Time frame	February 16th- April 27th 2026
Deviation	Monitoring: Baxter has not yet fully demonstrated a sufficiently documented and systematic approach for risk-based follow-up compliance with the contractual terms in the supply chain for the sampled product.
Suppliers action	1. Engage an outside consultant to guide Baxter with updating our approach for supplier engagement and ESG-risk management, aligned to international frameworks (e.g., OECD) and industry practices. (completed)

	2. Baxter will demonstrate its risk-based approach to monitor compliance with contractual terms in the end to end supply chain, with particular focus on the most significant risks identified. To achieve this, we plan to (not exhaustive): 2.1. Enhance the process to identify the high-risk suppliers for follow-up assessment and update policies and process documents to reflect systematic approach to follow-up with high-risk suppliers. 2.2. For identified suppliers, continue implementing relevant follow-up activities (e.g., self-assessments, desktop assessments, inspections and third-party audits), as needed. In the time frame specified, Baxter will focus on performing monitoring activities for the in-scope product (subject to supplier response and availability)
Time frame	February 16th- April 27th 2026